SRRK — Scholar Rock Holding Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1727196 ·
Last close
$48.63
Market Cap
$5.92B
52W High
$61.76
52W Low
$27.07
ADV30
1,842,467
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -108,901,000 | -109,896,000 | 523,543,000 | 437,091,000 | 269,759,000 |
| Mar 2026 | 0 | — | -102,016,000 | -105,510,000 | 535,254,000 | 430,543,000 | 259,241,000 |
| Dec 2025 | 0 | — | -91,896,000 | -90,965,000 | 404,272,000 | 323,527,000 | 158,784,000 |
| Sep 2025 | 0 | — | -103,550,000 | -102,220,000 | 411,718,000 | 286,770,000 | 166,723,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-296,827,000
Investing CF
$87,832,000
Financing CF
$494,660,000
CapEx
$-185,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.45
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,516,060,000
Inventory
—
Receivables
$1,959,000
ST Investments
$54,997,000
EBIT TTM
$-397,903,000
Pretax Income TTM
$-408,591,000
Interest Exp TTM
$10,688,000
Analysts
16
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -384,645,000 | -377,939,000 | 404,272,000 | 158,784,000 | 245,488,000 | -300,035,000 |
| Dec 2024 | 0 | -252,054,000 | -246,294,000 | 474,922,000 | 106,288,000 | 368,634,000 | -200,949,000 |
| Dec 2023 | 0 | -171,295,000 | -165,789,000 | 311,035,000 | 85,817,000 | 225,218,000 | -145,226,000 |
| Dec 2022 | 33,193,000 | -134,370,000 | -134,502,000 | 358,168,000 | 97,933,000 | 260,235,000 | -132,694,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.33
Max Pain — expiry 2026-10-16
max pain strike: $50.00 · spot: $48.63 · call oi: 2,918 · put oi: 1,587
Expected Move to 2026-10-16:
±$4.26
(8.76%) —
implied range
$44.37 –
$52.89
· ATM straddle on $50.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGON | CG Oncology, Inc. | $5.95B | $67.15 | — |
| CRSP | CRISPR Therapeutics AG | $5.24B | $54.23 | — |
| IMVT | Immunovant, Inc. | $6.88B | $33.30 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $4.98B | $11.00 | — |
| ADPT | Adaptive Biotechnologies Corp | $4.70B | $29.43 | — |
News headlines (Yahoo Finance, 1h cache)
Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says
2026-09-25 16:35 · Yahoo
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-21 16:00 · Yahoo
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
2026-09-18 10:43 · Yahoo
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?
2026-09-17 04:06 · Yahoo
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions
2026-09-15 23:16 · Yahoo
Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says
2026-09-14 16:17 · Yahoo
Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy
2026-09-14 12:08 · Yahoo
Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump
2026-09-14 11:41 · Yahoo
Scholar Rock SMA drug approved by FDA
2026-09-14 09:00 · Yahoo
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
2026-09-11 23:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.